Life Technologies Delivers Enhanced Next-Generation Genomic Analysis Technology for Large-Scale Resequencing Projects – SOLiD™ 3 Plus Enables Higher Throughput, Decreased Cost, and Faster Data Analysis on Life Science Industry’s Most Accurate Sequencing Platform

CARLSBAD, Calif. — Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE) today announced the commercial availability of the SOLiD™ 3 Plus System, an enhanced next-generation genomic analysis platform designed to allow researchers to move one step closer to performing mainstream sequencing of personal genomes for clinical research and personalized medicine. The technical enhancements to SOLiD 3 Plus include higher throughput, decreased run costs, and faster data analysis which deliver on a roadmap that enables scientists to sequence entire genomes in a more cost-effective and easy manner.

The SOLiD 3 Plus System, distinguished by its unmatched accuracy, is capable of generating more than 60 gigabases of mappable sequence data per run, at a 20% lower cost per sequencing run than previously possible. The combination of increased throughput, which equates to an approximate 50% decrease in cost per gigabase, shorter run times, and improved data analysis makes the SOLiD technology the ideal choice for large-scale resequencing genomic projects.

An advanced software solution, BioScope™, has been introduced and provides an integrated framework for data analysis, which allows researchers to benefit from smaller data file sizes while delivering faster mapping times. The addition of BioScope enables researchers to export data into a standard base sequence format, enabling the combination of data from multiple sequencing platforms into a single project-based analysis, and allows direct comparison of data from multiple next-generation sequencing platforms. This has proven to be beneficial in large-scale genomic studies, such as the 1000 Genomes Project.

Dr. Hans Lehrach, head of the Vertebrate Genomics Department at the Max Planck Institute for Molecular Genetics, is currently utilizing four SOLiD Systems for the 1000 Genomes Project and various other projects. Dr. Lehrach’s work is focused on the fields of cancer genomics, genome analysis and systems biology with particular interest in cellular and molecular mechanisms of cancer and other diseases. His research team currently uses the SOLiD System for a range of genomic studies, including whole genome resequencing, methylation analysis, miRNA and targeted resequencing.

Dr. Hans Lehrach, head of the Vertebrate Genomics Department at the Max Planck Institute for Molecular Genetics

“In our view, next-generation sequencing is a key step to the future of personalized medicine. Due to its high accuracy, and its relatively low sequencing costs, the SOLiD platform is clearly a major contributor in this development. The SOLiD 3 Plus technology in particular will enable the targeted resequencing of larger sized panels of individuals, especially in the field of cancer.”

Kip Miller, President, Genetic Systems Division at Life Technologies

“The delivery of these new performance attributes demonstrates Life Technologies’ commitment to furthering innovation in advanced genomic analysis technologies, and cements the SOLiD System as the most scalable platform on the market. We believe the SOLiD System is the next-generation sequencing technology platform of choice for a broad range of advanced genomics research, including system biology and disease studies.”

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

Copyright 2009. Life Technologies Corporation. All rights reserved. AB (Design), and Applied Biosystems are registered trademarks and SOLiD are trademarks of Life Technologies or its subsidiaries in the United States and/or certain other countries.